Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Participants With Neovascular Age-Related Macular Degeneration

NCT05210803 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05210803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05210803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Participants With Neovascular Age-Related Macular Degeneration
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
December 20, 2021
Completion date
July 31, 2031
Enrollment
116 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)